Parallel Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,982
| Closed | -$261K | – | 3737 |
|
|
2025
Q1 | $261K | Buy |
1,982
+27
| +1% | +$3.37K | 0.01% | 840 |
|
|
2024
Q4 | $163K | Buy |
1,955
+64
| +3% | +$5.26K | ﹤0.01% | 1023 |
|
|
2024
Q3 | $138K | Buy |
1,891
+277
| +17% | +$20.8K | ﹤0.01% | 1106 |
|
|
2024
Q2 | $111K | Buy |
1,614
+15
| +0.9% | +$1.04K | ﹤0.01% | 1136 |
|
|
2024
Q1 | $111K | Buy |
1,599
+35
| +2% | +$2.41K | ﹤0.01% | 1121 |
|
|
2023
Q4 | $112K | Buy |
1,564
+219
| +16% | +$12.6K | ﹤0.01% | 1069 |
|
|
2023
Q3 | $70.1K | Buy |
1,345
+113
| +9% | +$6.58K | ﹤0.01% | 1237 |
|
|
2023
Q2 | $78K | Hold |
1,232
| – | – | ﹤0.01% | 1188 |
|
|
2023
Q1 | $66.7K | Sell |
1,232
-1,272
| -51% | -$61.5K | ﹤0.01% | 1232 |
|
|
2022
Q4 | $133K | Sell |
2,504
-3
| -0.1% | -$150 | 0.01% | 876 |
|
|
2022
Q3 | $117K | Buy |
2,507
+3
| +0.1% | +$157 | 0.01% | 898 |
|
|
2022
Q2 | $143K | Sell |
2,504
-22
| -0.9% | -$1.25K | 0.01% | 826 |
|
|
2022
Q1 | $152K | Sell |
2,526
-118
| -4% | -$6.13K | 0.01% | 834 |
|
|
2021
Q4 | $138K | Sell |
2,644
-6
| -0.2% | -$252 | 0.01% | 890 |
|
|
2021
Q3 | $99K | Buy |
2,650
+150
| +6% | +$5.21K | ﹤0.01% | 988 |
|
|
2021
Q2 | $102K | Hold |
2,500
| – | – | ﹤0.01% | 949 |
|
|
2021
Q1 | $85K | Hold |
2,500
| – | – | ﹤0.01% | 955 |
|
|
2020
Q4 | $80K | Hold |
2,500
| – | – | ﹤0.01% | 898 |
|
|
2020
Q3 | $64K | Buy |
+2,500
| New | +$57K | ﹤0.01% | 970 |
|
Other funds holding ITCI
Parallel Advisors's ITCI Position: Q2 2025 in Review
Parallel Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,982 shares — an estimated $261K sold.
Parallel Advisors first reported a position in ITCI in Q3 2020 and held it in 19 quarters. The position peaked at $261K in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Parallel Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Parallel Advisors sold 1,982 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $261K.
- Parallel Advisors first reported a position in Intra-Cellular Therapies Inc. in Q3 2020 and held it in 19 quarters.
- Parallel Advisors's Intra-Cellular Therapies Inc. position peaked at $261K in Q1 2025.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Parallel Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.